PharmaShots

MAY 12, 2023

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

FDA 40

FDA Chemotherapy Immunization Hospitals 40

PharmaShots

FEBRUARY 3, 2023

4D Molecular Therapeutics Receives the US FDA’s IND Clearance of 4D-150 for the Treatment of Diabetic Macular Edema Date: Feb 03, 2023 | Tags: 4D Molecular Therapeutics, 4D-150, Diabetic Macular Edema, Regulatory, US, FDA, IND AstraZeneca and Amgen Receive the US FDA’s Approval of Tezspire (tezepelumab) for the Treatment of Severe Asthma (..)

FDA 40

FDA Labelling 40

PharmaShots

MAY 5, 2023

Chiesi Global Rare Diseases and Protalix BioTherapeutics Receive EC’s Marketing Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease Date: May 05, 2023 | Tags: Chiesi Global Rare Diseases, Protalix BioTherapeutics, PRX-102, pegunigalsidase alfa, Fabry Disease, Regulatory, EC, Marketing Authorization Kinoxis Therapeutics (..)

FDA 40

FDA 40

PharmaShots

MAY 26, 2023

Takeda and HUTCHMED's Fruquintinib Receives Priority Review from the US FDA to Treat Metastatic Colorectal Cancer Date: May 26, 2023 | Tags: Takeda, HUTCHMED, Fruquintinib, Metastatic Colorectal Cancer, Regulatory, Priority Review, US, FDA Gilead Receives EMA’s CHMP Positive Opinion to Extend the Use of Veklury (remdesivir) for COVID-19 Date: (..)

FDA 40

FDA 40

PharmaShots

FEBRUARY 17, 2023

Iveric Bio Reports the US FDA Acceptance of NDA and Granted Priority Review of Avacincaptad Pegol for Geographic Atrophy Date: Feb 17, 2023 | Tags: Iveric Bio, Avacincaptad Pegol, Geographic Atrophy, Regulatory, US, FDA, NDA, Priority Review ALX Oncology Reports the First Patient Dosing of Evorpacept in the P-I Study (ASPEN-07) for the Treatment of (..)

FDA 40

FDA Vaccines 40

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 40

FDA Immunization 40

PharmaShots

MAY 19, 2023

Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US Date: May 19, 2023 | Tags: Alimera, EyePoint Pharmaceuticals, Yutiq, Iluvien, chronic non-infectious uveitis, US, Pharma Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A Date: May 19, 2023 | Tags: Sobi, Efanesoctocog Alfa, (..)

Medical Schools 40

Medical Schools FDA Immunization Vaccines 40

Pharmaceutical Technology

MAY 1, 2023

Under the deal terms, Shunxi will have licence to develop, manufacture, and commercialise CTH-004 to treat several solid tumours including ovarian cancer in Greater China, including Hong Kong, Taiwan, Mainland China, and Macao. In animal models of ovarian cancer, it demonstrated promising results.

52

52

pharmaphorum

DECEMBER 23, 2022

There’s been huge progress in treatments for blood cancer in recent years – but drawbacks of expensive CAR-T cell and injected antibody therapies have led drug developers to look at novel oral therapies as patient-friendly alternatives. These are particularly important in the progression of certain blood cancers.

Immunization 52

Immunization Hospitals Vaccines 52

pharmaphorum

DECEMBER 23, 2021

Daiichi Sankyo has been granted breakthrough status by the FDA for patritumab deruxtecan, a HER3-targeted antibody-drug conjugate (ADC) in clinical trials for lung cancer. The post FDA gives Daiichi Sankyo’s HER3 drug a breakthrough tag appeared first on. Daiichi Sankyo and AZ are close collaborators in the ADC arena.

FDA 72

FDA Chemotherapy 72

Pharmaceutical Technology

DECEMBER 5, 2022

Collectively, cannabinoid receptors (CB1 and CB2) are currently the most popular targets in preclinical stage of development, with 391 drugs tagged in total. This is closely followed by CB2 receptors in second place. This is followed by epilepsy at 8% of the pipeline and multiple sclerosis at 7% of the pipeline.

Controlled Substances 98

Controlled Substances Compounding Immunization 98

pharmaphorum

APRIL 5, 2022

Immunocore now has approval on both side of the Atlantic for Kimmtrak – the first cancer therapeutic based on T cell receptor (TCR) technology – after getting a green light from the European Commission. Uveal melanoma is a rare cancer of the eye, which in the majority of patients is localised. ” Image by Pexels from Pixabay

Labelling 52

Labelling Chemotherapy Immunization 52

The Checkup by Singlecare

NOVEMBER 2, 2023

GLP-1 drugs are effective: There is a substantial body of scientific research supporting the effectiveness of these medications for several weight-related health concerns. However, continued research is needed to understand the long-term risks and benefits better. RELATED: What is the best diabetes drug for weight loss? per fill.

Insurance 52

Insurance FDA Adverse Reactions Hospitals 52

pharmaphorum

JANUARY 5, 2021

The FDA’s breakthrough status is for tiragolumab plus Tecentriq is the first for a TIGIT drug, and covers the first-line treatment of patients with advanced-stage non-small cell lung cancer (NSCLC) that expresses high levels of PD-L1. The post Roche nabs breakthrough tag for TIGIT cancer immunotherapy appeared first on.

Chemotherapy 52

Chemotherapy Immunization FDA Labelling 52

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Immunization Vaccines 52

pharmaphorum

JANUARY 21, 2022

“This evolution is leading to additional health benefits and health gains, but they are accompanied by major concerns, as very high price tags raise questions about their affordability.”. By 2026, she said, more than half of all public spend on medicines in Europe will be on cancer drugs for just 2% to 3% of the patient base.

Insurance 52

Insurance Vaccines 52

PharmaShots

MARCH 9, 2023

Education: She is a Post Graduate Research Fellow in Gastroenterology and Immunology from Stanford University School of Medicine. Other Affiliations: Alison works as a visiting researcher at Imperial College's Institute of Biomedical Engineering. Designation: Chief Scientific Officer Previous company: Toumaz UK Ltd. (15

FDA 40

FDA Pharmaceutical Companies Pharmaceutical Companies Immunization 40

pharmaphorum

NOVEMBER 28, 2022

The Linux Foundation AI & Data Foundation will house the software, which will now be available for any researcher to use for similar collaborative-data AI projects. “Researchers can now leverage privacy-preserving and secure federated learning software to drive cutting-edge collaborative medical research. .

Hospitals 72

Hospitals 72

pharmaphorum

OCTOBER 4, 2022

In this article, Ben Hargreaves takes a look at the renewed effort to tackle deaths from cancer in the US through the Cancer Moonshot. Central to the initiative is the aim to gather data from willing participants that can provide greater insights into cancer development and treatment over time. Building a bank.

Documentation 100

Documentation Data Entry HIPAA Insurance 100

Roots Analysis

SEPTEMBER 13, 2023

These molecules can be conjugated with various modalities, such as haptens, enzymes, isotopes, fluorescent tags, carrier proteins, polymers, particle conjugates and photoreactive molecules. Bioconjugation is a subset of conjugation where one of the entity is a biomolecule, such as protein or an antibody.

Labelling 40

Labelling 40

pharmaphorum

FEBRUARY 26, 2021

Its founder, Dr Paul Janssen, is recognised as one of the most innovative and prolific pharmaceutical researchers of the 20th century. Dr Paul Janssen is recognised as one of the most innovative and prolific pharmaceutical researchers of the 20th century”. It was in 1961 that Belgium’s Janssen Pharmaceutica N.V.

Vaccines 122

Vaccines Labelling Communication 122

The Checkup by Singlecare

JUNE 21, 2023

Being obese and overweight leads to an increased risk of serious health issues, including high cholesterol, hypertension, stroke, cancer, and death. And research has shown that liraglutide is effective at weight loss and maintenance in individuals with or without Type 2 diabetes. Weight loss is critical to minimizing PCOS symptoms.

Insurance 98

Insurance FDA Compounding Compounding Pharmacies 98

European Pharmaceutical Review

NOVEMBER 10, 2022

Advanced light microscopy techniques have emerged as a foundation of biomedical research, capable of visualising cellular functions at very high resolution whilst being minimally invasive to the cells or tissues of interest. This will help researchers to understand how formulation can improve cellular uptake to be more efficient.

Labelling 96

Labelling Compounding 96

European Pharmaceutical Review

DECEMBER 27, 2023

This data has been captured by CAR T-cell registries that were established first by the Center for International Blood and Marrow Transplant Research (CIBMTR) and later by the European Society for Blood and Marrow Transplantation (EBMT). This is in addition to its considerable price tag. Center for Biologics Evaluation and Research.

Adverse Reactions 83

Adverse Reactions Immunization Medical Schools Chemotherapy 83

STAT

DECEMBER 15, 2023

million price tag is nearly $1 million higher than its rivals’, even though its own treatment has a serious safety warning about a blood cancer risk. The treatment, Lyfgenia, was approved along with another sickle cell gene therapy, Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics. But Bluebird’s $3.1

Insurance 96

Insurance FDA 96

Pharmaceutical Technology

MARCH 17, 2023

Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic. In some cases, she said, “[drug] innovation would have been otherwise hindered by their price tag alone”.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies Communication 102